Contribution of fibrin glue in the surgery of cyanogenic and non-cyanogenic congenital cardiopathies: retrospective cohort study.
Cardiac Surgical Procedures
/ adverse effects
Child
Child, Preschool
Cyanosis
/ diagnosis
Erythrocyte Transfusion
Female
Fibrin Tissue Adhesive
/ adverse effects
Heart Defects, Congenital
/ complications
Humans
Infant
Length of Stay
Male
Morocco
Plasma
Platelet Transfusion
Postoperative Hemorrhage
/ etiology
Retrospective Studies
Time Factors
Tissue Adhesives
/ adverse effects
Treatment Outcome
Congenital cardiopathies
Cyanogenic
Fibrin glue
Non-cyanogenic
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
16 05 2019
16 05 2019
Historique:
received:
17
07
2017
accepted:
07
05
2019
entrez:
18
5
2019
pubmed:
18
5
2019
medline:
19
3
2020
Statut:
epublish
Résumé
Postoperative bleeding in cardiovascular surgery is a frequent and complicated situation for the surgical team, and may also be responsible for significant hospital expenditures. Fibrin glue are indicated in surgery to improve hemostasis when conventional techniques such as compression, sutures or electrocoagulation are insufficient. Through this study, we tried to study the contribution of fibrin glue to the improvement of the clinical parameters (volume of postoperative bleeding, length of stay in intensive care, volume of blood transfusion ...) in two populations having undergone cardiac surgery, one in which we used the fibrin glue and one without fibrin glue. This was a retrospective cohort study conducted in the cardiovascular surgery department of our Hospital in Rabat between June 2012 and June 2015. Fibrin glue (Tissucol® of BAXTER) was used in one group with an haemostatic aim. The pre and post-operative clinical data of the patients were analyzed and compared with data from patients who were operated without the use of fibrin glue because it was not yet available in the hospital. The clinical parameters were collected analyzed using the SPSS 13.0 software. One hundred ten patients were included in this study. The fibrin glue was used intraoperatively in 55 patients and not used in 55 patients. 43 (39.1%) had cyanogenic diseases and 67 (60.9%) had non-cyanogenic pathologies. The volume of transfused red blood cells was lower in patients in whom we used biological glue (p = 0.005), as well as the number of days spent in intensive care (p = 0.02). However, the difference was not significant between the two groups for other parameters such as bleeding volume per kg, the number of units of fresh frozen plasma and the platelet units count transfused. The results we found show that fibrin glue reduces the duration of hospitalization in resuscitation and reduces the number of units of transfused red blood cells to patients after surgery. However, it does not reduce significantly the total postoperative bleeding volume per weight, the number of fresh frozen plasma units or platelets units transfused. The fibrin glue could therefore be of moderate benefit in pediatric cardiac surgery.
Sections du résumé
BACKGROUND
Postoperative bleeding in cardiovascular surgery is a frequent and complicated situation for the surgical team, and may also be responsible for significant hospital expenditures. Fibrin glue are indicated in surgery to improve hemostasis when conventional techniques such as compression, sutures or electrocoagulation are insufficient. Through this study, we tried to study the contribution of fibrin glue to the improvement of the clinical parameters (volume of postoperative bleeding, length of stay in intensive care, volume of blood transfusion ...) in two populations having undergone cardiac surgery, one in which we used the fibrin glue and one without fibrin glue.
METHODS
This was a retrospective cohort study conducted in the cardiovascular surgery department of our Hospital in Rabat between June 2012 and June 2015. Fibrin glue (Tissucol® of BAXTER) was used in one group with an haemostatic aim. The pre and post-operative clinical data of the patients were analyzed and compared with data from patients who were operated without the use of fibrin glue because it was not yet available in the hospital. The clinical parameters were collected analyzed using the SPSS 13.0 software.
RESULTS
One hundred ten patients were included in this study. The fibrin glue was used intraoperatively in 55 patients and not used in 55 patients. 43 (39.1%) had cyanogenic diseases and 67 (60.9%) had non-cyanogenic pathologies. The volume of transfused red blood cells was lower in patients in whom we used biological glue (p = 0.005), as well as the number of days spent in intensive care (p = 0.02). However, the difference was not significant between the two groups for other parameters such as bleeding volume per kg, the number of units of fresh frozen plasma and the platelet units count transfused.
CONCLUSIONS
The results we found show that fibrin glue reduces the duration of hospitalization in resuscitation and reduces the number of units of transfused red blood cells to patients after surgery. However, it does not reduce significantly the total postoperative bleeding volume per weight, the number of fresh frozen plasma units or platelets units transfused. The fibrin glue could therefore be of moderate benefit in pediatric cardiac surgery.
Identifiants
pubmed: 31096916
doi: 10.1186/s12872-019-1102-7
pii: 10.1186/s12872-019-1102-7
pmc: PMC6524237
doi:
Substances chimiques
Fibrin Tissue Adhesive
0
Tissue Adhesives
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Références
J Card Surg. 2013 May;28(3):238-47
pubmed: 23578196
Ann Thorac Surg. 1995 Nov;60(5):1255-62
pubmed: 8526609
Nouv Presse Med. 1977 Oct 22;6(35):3221-3
pubmed: 563061
Blood Rev. 1991 Dec;5(4):240-4
pubmed: 1782483
N Engl J Med. 1995 Jun 1;332(22):1463-6
pubmed: 7739682
Eur J Cardiothorac Surg. 2007 Oct;32(4):567-72
pubmed: 17761433
J Long Term Eff Med Implants. 1998;8(2):87-101
pubmed: 10181375
Ann Thorac Surg. 2000 May;69(5):1376-82
pubmed: 10881808
Thromb Haemost. 1997 Feb;77(2):270-7
pubmed: 9157580
Am Surg. 2004 Apr;70(4):307-11
pubmed: 15098782
Eur J Cardiothorac Surg. 2002 Aug;22(2):200-5
pubmed: 12142185
Ann Thorac Surg. 1984 Oct;38(4):411-3
pubmed: 6207785
Am J Surg. 2001 Aug;182(2 Suppl):21S-28S
pubmed: 11566473
Thorac Cardiovasc Surg. 1983 Jun;31(3):142-6
pubmed: 6192519
J Vasc Surg. 2006 Nov;44(5):1002-1009; discussion 1009
pubmed: 17020801
J Am Coll Surg. 2003 Aug;197(2):243-52; discussion 252-3
pubmed: 12892806
Eur J Cardiothorac Surg. 1996;10(9):727-33
pubmed: 8905274
Surgery. 2001 Apr;129(4):445-50
pubmed: 11283536
J Biomater Appl. 1993 Apr;7(4):309-52
pubmed: 8473984
J Thorac Cardiovasc Surg. 1992 Oct;104(4):1092-9
pubmed: 1405668
J Thorac Cardiovasc Surg. 2003 Sep;126(3):666-70
pubmed: 14502137
J Vasc Surg. 2008 Jun;47(6):1266-73
pubmed: 18440754
J Thorac Cardiovasc Surg. 1989 Feb;97(2):194-203
pubmed: 2464722